Oregon Health & Science University has enrolled the first West Coast participant in a clinical trial using CRISPR gene editing to treat high cholesterol. The multicenter study, which is testing a drug known as CTX310, aims to provide a one-time therapy to reduce cholesterol levels in patients at high risk for cardiovascular disease.
Trial Enrollment at Oregon Health & Science University
Oregon Health & Science University (OHSU) has joined a global effort to test a new, one-time gene-editing treatment for patients struggling with dangerously high cholesterol. As the only center on the West Coast participating in the trial, OHSU is currently enrolling individuals between 18 and 75 years of age who have been unable to manage their low-density lipoprotein (LDL) or triglyceride levels through standard medications, such as statins.
The first participant enrolled at the site is a 54-year-old woman.
CTX310 Uses CRISPR Gene Editing to Lower Cholesterol
The trial, sponsored by CRISPR Therapeutics, evaluates the safety and efficacy of a drug identified as CTX310. The treatment utilizes a lipid nanoparticle using CRISPR gene editing to inhibit the function of a gene associated with cholesterol.
“If it works safely, it could be a choice for any adult with high LDL at elevated risk for arthrosclerosis.”
Ahmad Masri, M.D., M.S., OHSU site investigator
By inhibiting the function of a gene associated with cholesterol via a one-time infusion, researchers hope to permanently lower a patient’s cholesterol burden.
Oregon Health & Science University has enrolled the first participant on the West Coast in a clinical trial using gene editing to reduce a form of high cholesterol known to raise the risk of heart attack and stroke. #OHSUResearch #CRISPR https://t.co/2NdSsK49BY pic.twitter.com/TLT9J6ms2A
Broader Findings on Gene-Targeting Potency
While the OHSU trial focuses specifically on cholesterol, broader research reported as of October 13, 2026, highlights how cholesterol-linked drugs are enhancing the precision of gene-targeting technologies. Scientists have observed that utilizing cholesterol’s natural affinity for cell membranes can help genetic material penetrate cellular barriers more effectively.
- Enhanced Delivery: The medication seems to boost how efficiently gene-editing tools are delivered, enabling genetic material to be targeted with greater precision.
- Potential for Broader Applications: It is suggested by researchers that this breakthrough could open the door to treating various genetic disorders beyond those currently being addressed.
- Safety and Efficacy: Preliminary data suggest that the drug linked to cholesterol may possess a positive safety profile, which is a critical factor in clinical environments.
Early findings reported by Phys.org on October 12, 2026, indicate that these drugs can significantly increase the potency of gene targeting. By facilitating the delivery of genetic material more effectively to specific cells, this therapeutic agent may pave the way for treating genetic disorders and conditions previously considered difficult to manage.
These gene-targeting treatments are being developed to treat various diseases, including those affecting the nervous system, by modifying specific genes. This brings hope for more effective treatments for neurological diseases that have been hard to treat.
Researchers believe that increasing the potency of gene therapies could lead to better health outcomes and an improved quality of life for patients. More effective treatments might reduce healthcare costs, potentially making advanced therapies more accessible.
“If it works safely, it could be a choice for any adult with high LDL at elevated risk for arthrosclerosis. Initially, it would be most useful for patients who can’t tolerate statins or other alternative medications — or they’re on those medications and still have high cholesterol.”
Ahmad Masri, M.D., M.S., OHSU site investigator
Ahmad Masri, M.D., M.S., who serves as an associate professor of medicine (cardiovascular medicine) in the OHSU School of Medicine, noted that the initial participants are those most acutely affected by high cholesterol and are thus most likely to benefit. He stated, It has the potential to transform the lifetime of an individual with dangerously high levels of cholesterol.
With an estimated 86 million adults in the United States affected by high cholesterol, the outcome of this multicenter, open-label trial—one of 17 worldwide—is being closely watched for its potential to revolutionize treatment methods for patients with limited options. The overarching goal is to provide a one-time therapy that reduces a patient’s cholesterol burden over the following decades.